We have previously shown that refractory neuroendocrine tumors can respond to moderate doses of chemoradiotherapy. We completed a dose-escalation phase I/II trial combining hepatic arterial (HA) chemotherapy, chemoembolization, and dose-escalated whole liver radiotherapy to determine the maximum safe dose of radiation that could be delivered and to make a preliminary assessment of response. From 2002From to 2009 patients with symptomatic neuroendocrine liver metastases who failed somatostatin analog therapy were enrolled. HA fluorodeoxyuridine, leucovorin, and streptozotocin were delivered, as concurrent whole liver radiotherapy was dose escalated from 24 to 32 Gy in 2 Gy fractions, with a target rate of dose-limiting grade Z3 radiation-induced liver disease of 10%. Eight weeks later, for patients without grade Z3 liver or grade Z4 any toxicity, a 72-hour infusion of HA fluorodeoxyuridine and leucovorin was given, followed by transarterial chemoembolization.
N euroendocrine tumors (NET) are relatively rare malignant neoplasms whose incidence and prevalence have increased significantly over the past 4 decades. 1 Hepatic spread occurs in 30% to 85% of NET, leading to significant abdominal pain and hormonal syndromes. 2 Treatment options for NET metastatic to the liver often include systemic therapy, but more directed therapies can span from treatment of isolated lesions including surgery, ablation, transarterial chemoembolization (TACE), radioembolization, or high-dose radiotherapy; to rarely, treatment of the whole liver with transplantation. 3, 4 For all liver-directed therapies, recurrences and progression are frequent, highlighting the need for additional therapeutic options. The hypervascular nature of NET and their dependence upon the hepatic artery (HA), make them attractive for chemoembolization, a process in which blood flow to a tumor is blocked at the same time a chemotherapy agent is delivered. This treatment can produce both clinical and radiographic responses in patients with neuroendocrine unresectable liver metastases. 5, 6 Although long considered "radioresistant" tumors, NET respond to moderate doses of RT, with a 39% overall response rate and 90% palliation rate. 7 Previously we have combined low-dose (24.2 in 2.2 Gy fractions) whole liver radiotherapy (WLRT) with concurrent HA fluorodeoxyuridine (FUDR)/leucovorin (LV) and subsequent chemoembolization with mitomycin C (MMC), and reported a 75% response rate. 8 We hypothesized that higher doses of radiation could safely be delivered to the whole liver and combined with HA streptozotocin (STZ), a glucosamine-containing antibiotic with activity specifically in NET, 9 followed by chemoembolization. Here we report the results of phase I clinical trial to determine the dose of WLRT that could be delivered to symptomatic patients with extensive hepatic neuroendocrine metastases concomitantly with HA FUDR/LV and STZ followed by additional HA FUDR/LV and subsequent chemoembolization with MMC, and to make a preliminary response estimate for this approach.
MATERIALS AND METHODS
This study was approved and monitored by the Institutional Review Board of the University of Michigan, and all patients provided written informed consent before enrollment in the study. Eligible patients were adults (Z18 y) with histologic proof of NET and dominant liver metastases, who were symptomatic, and/or had a progressive disease (PD) in the liver despite treatment with maximal doses of a somatostatin analog. The liver metastases were deemed not treatable with local therapy such as resection or radiotherapy (either fractionated focal therapy or stereotactic body radiotherapy). Patients were required to have a Karnofsky performance status of Z80%, expected life expectancy >4 months, and adequate bone marrow (granulocyte count > 2000/mm 3 , platelet count > 90,000/ mm 3 ), hepatic (serum albumin > 2.0 g/dL, total bilirubin < 2 mg/dL, international normalized ratio < 1.2), and renal (creatinine < 2.0% mg/dL) function. Patients previously treated with chemotherapy or nonhepatic radiation were eligible as long as they had recovered from all toxicity of prior therapy and had terminated chemotherapy at least 4 weeks before treatment. Exclusion criteria included cirrhosis, ascites, previous abdominal radiation, bleeding diathesis, severe peripheral arterial disease, portal vein thrombosis, and portal hypertension with hepatofugal flow.
To avoid the confounding element caused by chemotherapy and chemoembolization-induced toxicities, the treatment was divided into 2 parts (Fig. 1) For WLRT that was initiated on the second day of chemotherapy, patients underwent CT-based simulation in an immobilization device, with images obtained at voluntary endexhale. The target volume encompassed the entire liver including any disease that extended beyond the margin of normal liver. An additional caudal margin was used to account for respiratory motion, the magnitude of which was determined by the cranial-caudal diaphragm motion observed on fluoroscopy. RT was delivered in 2 Gy daily fractions using 15 to 16 MV photons. If it was necessary to treat >90% of 1 kidney in excess of 20 Gy to encompass the entire liver, then >90% of the contralateral kidney received <18 Gy. The prescribed dose of WLRT was planned to be escalated from 24 to 32 Gy in 2 Gy increments using time-to-event continual reassessment method (TITE-CRM; detailed below), stopping earlier if the rate of dose-limiting toxicity (DLT), which included grade Z3 radiation-induced liver disease (RILD), after the first part of 
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Evaluation for adverse events and response (at 8 weeks) 2 FIGURE 1. Treatment scheme. WLRT was delivered daily starting on day 2 (generally Monday to Friday), until the prescribed dose was completed. Patients were allowed to begin mid-week if necessary due to scheduling constraints, and to receive radiation on Saturdays during their treatment. The 2 parts were at least 8 weeks apart to allow time for detection of radiation-induced liver disease. Initial protocol laboratory eligibility criteria were to be met before the second part being initiated. FUDR/LV indicates fluorodeoxyuridine/ leucovorin; STZ, streptozotocin; WLRT, whole liver radiotherapy.
the treatment expected to be Z10%. Although dose-escalation scheme was based on RILD toxicity only, patients who experienced any other grade Z4 toxicity, excluding transient liver enzymes elevations lasting <2 weeks, and a carcinoid crisis, in 2 months after RT had their treatment stopped. The second part of treatment included FUDR (3 mg/m 2 /d) and LV (300 mg/m 2 /d) administered as a 72-hour continuous infusion through a newly placed HA catheter. Embolization was then performed using particulate transcatheter polyvinyl alcohol (0.5 cm 3 of dry 255 to 350 mm particles) and MMC (20 mg). All patients were given broad spectrum intravenous antibiotics starting 12 hours before chemoembolization and continuing for 36 hours, or until afebrile for 48 hours, whichever was longest.
Patients underwent daily history and physical examinations and laboratory evaluations every other day during the infusional portions of treatment. In addition, patients underwent history and physical examinations and laboratory evaluations at weeks 2, 4, and 7 to 8 after the first part of the treatment, at weeks 2, 4, and 8 after the second part of the treatment, and every 6 months thereafter. Abdominal CT or MRI was performed before the treatment, 8 weeks after each part, and every 6 months thereafter. The primary end-points of the trial were the dose of WLRT which, when given with HA chemotherapy had a 10% risk of RILD, and the proportion of patients who having undergone the first part without experiencing RILD, developed grade Z4 toxicities (other than transient liver enzyme elevation and carcinoid crisis) after chemoembolization. The secondary endpoints of the study were objective response rates 2 months after each part of the treatment, freedom from local progression (FFLP) and overall survival (OS). Toxicities of the treatment were graded according to Common Terminology Criteria for Adverse Events v.3. Complete response (CR), partial response (PR), PD, and stable disease (SD) were defined according to Response Evaluation Criteria in Solid Tumors.
The trial was designed using the TITE-CRM that assumes a simple model for the time-to-occurrence of a toxic response as a function of radiation dose, and thereby allows continuous recruitment throughout the trial by accessing information from all subjects enrolled in the trial when allocating a new patient to a higher dose level. 10, 11 Initial estimates of the incidence of RILD required for the TITE-CRM algorithm at any dose level were calculated from the Lyman-type model of normal tissue complication probability. 12 According to this, the initial estimates of probabilities of dose-limiting RILD for each dose level of WLRT were 0.01 for 24 Gy, 0.02 for 26 Gy, 0.05 for 28 Gy, 0.1 for 30 Gy, and 0.15 for 32 Gy. When a patient was enrolled, the probability of RILD was estimated for each dose based on the initial estimates and the incidence of toxicity in patients already treated, weighted by the amount of time those patients have been followed. The dose that has toxicity closest to the target rate was selected. Dose escalation was restricted to one level between adjacent patients and could not be escalated unless at least 1 patient has completed the observation period for DLT at each previously tested radiation dose. The probability that the true rate of DLT exceeds 15% at 32 Gy was calculated from the posterior distribution, thus based on both the prior estimates and the observed data.
The follow-up times for FFLP and OS were calculated from the beginning of the treatment and continued until documented local progression or death, whichever came first. Survival probabilities were estimated using the Kaplan-Meier method.
RESULTS
Nineteen patients with symptomatic hepatic neuroendocrine metastases resistant to somatostatin analog therapy were enrolled between 2002 and 2009 (Table 1) . Although the majority of tumors (13 patients) were secretory, only 7 patients had clinically apparent reversible endocrine syndromes: 4 carcinoid syndrome, 2 Cushing syndrome, and 1 hypoglycemia. The majority (13 patients, 68%) had abdominal pain at the beginning of the trial. Eight patients were allocated to 24 Gy, 2 to 26 Gy, 1 to 28 Gy, 2 to 30 Gy, and 6 to 32 Gy of WLRT. Sixteen patients completed the first part of treatment as planned; 2 completed the first part with interruptions due to episodes of carcinoid crisis that required breaks for supportive care. One of the first patients allocated to 24 Gy dose level developed acute renal failure and thrombocytopenia (both grade 4) after 14 Gy of WLRT, both attributed to systemic effects of STZ. In 5 patients, STZ dose was reduced secondary to treatment-related adverse events including fatigue, renal dysfunction, and nausea and emesis. Thirteen patients received the full treatment dose of STZ, 5 reduced, and 1 none. The majority of moderate to severe adverse events that occurred during and immediately after the first part of the treatment were lymphopenia and temporary rise in liver function tests (all cases except 1). No patient developed dose-limiting RILD at any dose level. Two patients had carcinoid crisis, requiring intensive therapy, and cardiopulmonary resuscitation in 1 case. The last case, which was possibly precipitated by angiography, was accompanied by a grade 4 increase in liver transaminases and grade 3 hyperglycemia. One patient had grade 4 diarrhea and leucopenia accompanied by grade 3 hypoalbuminemia, potentially due to systemic effects of FUDR.
Eight patients did not complete the TACE part of the treatment. For 3 patients (16%), treatment was stopped intentionally before chemoembolization because of nonhepatic treatment-related grade 4 toxicities (renal failure, diarrhea) and grade 4 liver transaminases elevation, which was observed during and attributed to angiography procedure. Three patients discontinued their treatment because of exacerbation of existing medical conditions (none more than grade III) and deterioration of the performance status. A HA catheter could not be appropriately placed in 1 patient, and 1 patient refused. IQR indicates interquartile range; NOS, not otherwise specified; RFA, radiofrequency ablation; RT, radiotherapy.
Ultimately, 11 patients proceeded to chemoembolization. The second part of the treatment was well tolerated, with 1 episode of grade 4 carcinoid crises and frequent hepatic pain and fever (all except 2 cases were grade 1 to 2) which were managed successfully with antibiotics and pain medications. The probabilities of DLT were below the target rate for all doses of WLRT ( Table 2 ). The probability that the true rate of DLT exceeds 15% at 32 Gy is 11%.
RESPONSE AND SURVIVAL
Radiographic response rates were obtained 8 weeks after the completion of each part of treatment (Fig. 2 ). There were no CRs; 3 patients had PR (16%) and 16 (84%) patients had SD after the first part of the treatment. All 11 patients who proceeded to chemoembolization had SD after the second part of the treatment. Symptomatic relief after the completion of the protocol was reported by 16 patients (84%). Median FFLP for all patients was 35.3 months (95% CI, 9.3-58.9 mo) (Fig. 3) . Seven patients died of their disease during the study period, 3 patients died of causes unrelated to treatment (1 intracerebral hemorrhage, 1 preexisting medical problems, and 1 possible case of suicide), and 9 were still alive when the study was closed in July 2009. Median OS for all patients was 54.6 months (95% CI, 17.0 to N mo).
DISCUSSION
This study is a result of our long-standing interest in hepatic irradiation with radiosensitizers for hepatic primary and metastatic tumors. Our previous reports have demonstrated that HA FUDR can be safely combined with hepatic irradiation. 8, 13 Realizing the limits of WLRT dose escalation, we added chemoembolization with MMC, which resulted in higher response rates (both complete and partial) among patients with hepatobiliary tumors and noncolorectal liver metastases compared with patients with colorectal cancer (41% vs. 12%, P = 0.062). 8 Then HA STZ, a chemotherapeutic agent active in NET, was added in patients with metastatic neuroendocrine cancer to augment the antitumor activity of the regimen. Encouraged by responses to low-dose WLRT in patients with NET in the previous study, we conducted this radiation dose-escalation study. Our conclusions, based on treatment of 19 symptomatic patients with neuroendocrine hepatic metastases are that 32 in 2 Gy daily fractions of WLRT can be given safely with HA FUDR/LV and STZ, and that HA FUDR and chemoembolization with MMC can be safely delivered afterward. Chemotherapy-related and chemoembolization-related side effects were as expected after a dose reduction of STZ.
In a previous study, we found that previous alkylator chemotherapy increased the risk of RILD, and thus, we cautiously escalated whole liver dose with this new combination of STZ and chemoembolization. There was no RILD in any dose level. Analysis of predictive factors for RILD in this population of patients has revealed that patients with liver metastases are more tolerant to liver radiation than those with primary hepatobiliary malignancies. 12 The more indolent nature of NET, better functional status, and absence of risk factors commonly found in primary hepatobiliary cancers could account for the greater tolerability of liver to radiationinduced damage of this highly selective group of patients.
The 16% PR and 84% SD response rates, 35.3-month median FFLP and 54.6-month median OS observed in the study are difficult to compare with the published reports because of differences in design, patients, reported variables, and response evaluation criteria. Earlier reports on chemoembolization, and embolization and chemotherapy in NET cited radiographic regression rates of 60% and 80%, respectively, with progression-free survival that ranged from 35 months for patients with islet cell carcinomas to 49 months for patients with carcinoid tumors. 5, 8 A recent report on radiotherapy for local and metastatic pancreatic NET found 13% CR, 26% PR, 56% SD, 4% PD, and 90% symptomatic relief in patients receiving palliative treatment. The OS of 55 months in our current study compares favorably with the 24 months in that study, especially because all of our patients had symptomatic and/or PD, although over half of our patients had carcinoid tumors which generally have a relatively indolent course. A more recent report on HA radioembolization with 90 Y-resin microspheres in 42 patients with symptomatic unresectable neuroendocrine liver metastases described response rates similar to ours: 22.5% PR, 75% SD, and 2.5% PD. 14 In reality, higher response rates of different therapies for NET have not translated into better survival rates. In fact, recent reports on the beneficial effects of somatostatin longacting analog, 15 everolimus 16 and sunitinib malate 17 on progression free survival of patients with metastatic NET cited a dismal response rates of 2%, 5%, and 9.3%, respectively, while doubling the progression free survival from 4.6 to 6 months and from 11 to 14.3 months at the same time. Interestingly, everolimus, a mammalian target of rapamycin inhibitor, was also demonstrated to increase sensitivity of solid tumors to ionizing radiation, probably by targeting neoplastic vasculature. 18 Although never tested formally in the setting in NET, established survival benefits for patients with NET, oral formulation and infrequent serious side effects combined with radiosensitizing properties of everolimus could make this agent a potential candidate for upcoming combined treatment studies. The benefit and safety of either systemic therapy 16, 17, 19 or liver-directed therapeutic approaches, including external beam radiotherapy, radioembolization, and their sequencing strategies after the development of treatment resistance to systemic therapy is not clear, and should be a subject of future clinical studies.
In addition, with no observed RILD, another strategy would be to escalate WLRT dose further or add a boost to dominant areas of disease. TACE has been combined with high-dose focal radiotherapy for hepatocellular carcinoma with improved responses, 20, 21 and this may also be a promising approach for neuroendocrine metastases. However, with any 
